Cancer stem cells are rare tumor cells characterized by their ability to self-renew and to induce tumorigenesis. They are present in gliomas and may be responsible for the lethality of these incurable brain tumors. In the most aggressive and invasive type, glioblastoma multiforme (GBM), an average of about one year spans the period between detection and death [1] . The resistence of gliomas to current therapies may be related to the existence of cancer stem cells [2] [3] [4] [5] [6] . We find that human gliomas display a stemness signature and demonstrate that HEDGEHOG (HH)-GLI signaling regulates the expression of stemness genes in and the self-renewal of CD133 + glioma cancer stem cells. HH-GLI signaling is also required for sustained glioma growth and survival. It displays additive and synergistic effects with temozolomide (TMZ), the current chemotherapeutic agent of choice. TMZ, however, does not block glioma stem cell self-renewal. Finally, interference of HH-GLI signaling with cyclopamine or through lentiviral-mediated silencing demonstrates that the tumorigenicity of human gliomas in mice requires an active pathway. Our results reveal the essential role of HH-GLI signaling in controlling the behavior of human glioma cancer stem cells and offer new therapeutic possibilities.
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Results and Discussion
Previous work provided evidence for a role of HH-GLI signaling in gliomas [7] . SONIC HEDGEHOG (SHH) activates a signal-transduction cascade that includes the action of the membrane proteins PATCHED1 (PTCH1) and SMOOTHENED (SMOH), leading to the action of GLI transcription factors [8] . Analyses of a panel of fresh brain tumors ( Figure 1A , Table S1 in the Supplemental Data available online) demonstrated the ubiquitous and varied expression of HH-GLI pathway components including GLI1, SHH, and PTCH1, confirming the general presence of an active pathway ( Figure 1A , Figures S1A-S1C and Figure S2 ) because GLI1 transcription is the only reliable marker of pathway activity. GLI1 was the only gene overexpressed on average in all tumor types, as judged on the basis of the average expression levels of three separate cortical regions of normal brain tissue. PTCH1 levels were lower in glioblastoma multiformes (GBMs) [9] , and SHH was high only in a subset of lowgrade gliomas. Although some gliomas express SHH in tumor cells [7] , a subset with low expression localized it in new vessels, whereas PTCH1 was indeed expressed in tumor cells ( [7] ; Figure 1B ).
Gliomas showed a stemness signature ( Figure 1A , Figure S2 ) that included the expression of the stemness genes NANOG, OCT4, SOX2, and BMI1, centered over grade III gliomas but extending into neighboring grade IV (GBM) and grade II tumors ( Figure 1A ). Tumors in transition may display a mixed character, such as a stemness signature and multiforme appearance in GBM-4 and GBM-6 and low-grade pathology and a stemness signature in some grade II tumors ( Figure 1A ). In contrast, there was only a poor correlation between grade and a set of previously identified glioma prognostic markers ( Figure S3 ). Two medulloblastomas used as controls [7] expressed GLI1 but did not overexpress the same stemness gene set ( Figure 1A ). The stemness signature of grade III gliomas suggests the abundance of cancer stem cells in these tumors.
All but one adherent primary culture of gliomas tested decreased cell proliferation as measured by BrdU incorporation after 48 hr treatment with cyclopamine, a specific SMOH inhibitor [10] , as compared with tomatidine as control ( Figure 1C ). Inhibition was dose dependent and cumulative over time ( Figure S4A ). The GBM cell line U87 behaved similarly ( Figure 1C ), decreased GLI1 expression upon cyclopamine treatment (Figure S4B) , and showed complete cell death after 10 days of treatment ( Figure S4C ). However, drug removal after 5 days allowed culture recovery, indicating temporally distinct cytostatic and cytotoxic effects ( Figure S4C ). GLI RNA interference [11] demonstrated the general requirement of GLI1 and GLI2 in brain tumor-cell proliferation, with GLI1 knockdown having the strongest effects, as compared with an unrelated siRNA control ( Figure 1D ). As for prostate tumors [11] , most brain tumors tested had activation of the HH-GLI pathway at the level of SMOH in the membrane or above. However, because the one tumor that was insensitive to cyclopamine responded to GLI1 interference ( Figure 1D ), activation here likely took place on or downstream of SMOH. The levels of inhibition reflected lipofection efficiencies, and an independent set of siRNAs gave similar results ( Figures S5A and S5B ). Interference with GLI1 and GLI2 also increased apoptosis ( Figure 1F ). Longterm silencing in U87 cells increased cell death after interference with GLI1 but not GLI2 ( Figure S5C ), indicating their differential requirement for survival in these *Correspondence: ariel.ruizaltaba@medecine.unige.ch Figure S2 ). Gliomas are ranked by grade and by gene-expression pattern as GBM, glioblastoma mulitforme or grade IV astrocytomas (all primary GBMs); A, astrocytoma; OG, oligodendroglioma; and AG, anaplastic glioma. The roman numeral denotes World Health Organization grade, and the arabic numeral denotes the tumor number within our series. Two medulloblastomas (MB) are used as controls for HH-GLI pathway activity [7] . Domains of consistent (>50% of cases) GLI1 activity and of the stemness signature are boxed, and the names of the genes are highlighted. Figure 1D ), consistent with its rare role as a minor activator and its more common role as a major repressor of GLI targets [8] . GLI3 was found to mediate the effects of cyclopamine: Cells transfected with GLI3 siRNA or a control siRNA and then treated with this drug showed that the antiproliferative and proapoptotic effects of cyclopamine were reverted by inhibition of GLI3 ( Figures 1E and 1F ).
To test for a possible role of HH-GLI signaling in cancer stem cells, we have used glioma stem cell cultures (gliomaspheres) (Figures 2A and 2B ), which self-renew and mimic the original tumor after transplantation into the brains of immunocompromised mice [5] . Treatment with cyclopamine decreased their proliferation and increased apoptosis in a concentration-dependent manner ( Figures 2C and 2D ). Inhibition of cell proliferation was recapitulated by transduction with a recombinant lentiviral vector expressing an shRNA specific for SMOH (LV-shSMOH) after comparison with a control lentiviral vector (LV-control) ( Figure 2E ). Inhibition of SMOH mRNA by the LV-shSMOH was at 67% in U87 cells and at 66% in GBM-8 72 hr after transduction.
Long-term treatment and recovery assays showed that 20, but not 10, days of treatment with cyclopamine were sufficient to kill all gliomasphere cells because the culture did not recover after an additional 20 days without the drug ( Figure S6E ). In contrast, the DNAdamaging chemotherapeutic agent temozolomide (TMZ; [1] ) also affected the proliferation and survival of glioma cells ( Figures S6A-S6D ) but was unable to prevent recovery ( Figure S6F ). Importantly, TMZ showed additive or synergistic effects in different glioma stem cell cultures and in U87 cells with an intermediate dose (5 mM) of cyclopamine on the inhibition of cell proliferation and the enhancement of apoptosis ( Figures 2F  and 2G ).
Intracraneal xenografts of untransduced or LacZlentiviral-transduced GBM gliomaspheres induced the development of massive infiltrative gliomas in nude mice after 2.5 months ( Figure 3A ). These tumors expressed GLI1, SHH, and PTCH1 ( Figure S7) , consistent with the expression of these genes in gliomas by in situ hybridization [7] . Using a protocol with 10 4 GFPlentiviral-transduced gliomasphere cells injected into the striatum and left for 2 weeks prior to treatment for an additional 2 weeks, we showed that cyclopamine had a beneficial effect. Systemic intraperitoneal (i.p.) treatment with cyclopamine, but not with carrier alone, reduced glioma tumor volume ( Figure 3B ) and cell proliferation ( Figure 3C ). Similar effects were seen with subcutaneous xenografts of U87 glioma cells: Delivery of cyclopamine in and around the tumor inhibited all growth, and the tumors disappeared ( Figures 3I, 3J , and 3L), showing a size differential with controls as soon as the second day of treatment.
Similar results were obtained after the cell-autonomous knockdown of SMOH. LV-shSMOH reduced SMOH mRNA levels by 65%-85% in U87 and GBM-8 cells, reduced GLI1 levels by w45% in both, markedly reduced tumor volume, and reduced BrdU incorporation 2-3-fold ( Figures 3D, 3F, 3G , 3J, 3K, and 3M and data not shown). To further control any differences between the experimental and control injected cells, including insertion sites, we rendered LV-shSMOH silent and conditionally inducible by treatment with doxycycline (DOX) through cotransduction with LV-tTR-KRAB [12] . Two weeks after intracranial injection of 10 4 cotransduced GBM-8 cells (at >90% transduction efficiency), one half of the mice were treated with DOX for an additional 2 weeks, and the other half were left untreated. DOX treatment, inducing the silencing of SMOH, reduced tumor volume by w80% as compared with mice that did not receive DOX ( Figure 3E ). Long-term analysis of straight LV-shSMOH and LV-control-transduced GBM-8 cells demonstrated the greater survival of LV-shSMOH-harboring mice versus LV-control mice ( Figure 3H ).
The stemness signature of grade III gliomas but not of most GBMs contrasts with the ability of both to form gliomaspheres. If GBM cancer stem cells are simply less abundant than those in grade III tumors, the selection of cancer stem cells in gliomasphere cultures could yield a similar enrichment. The expression patterns of 25 selected genes in seven gliomasphere cultures (Figures 1A and 4A and Figure S8 ) identified a subgroup of genes displaying expression within a 2-fold variation from the mean, or overexpression, in all spheres. This included GLI1, PTCH1, NANOG, OCT4, SOX2, BMI1, and PCNA. The latter indicated similar proliferation of all sphere cultures. Different gliomaspheres therefore have active GLI1 function and might have similar numbers of cancer stem cells, assuming similar expression per cell.
To test for a link between HH-GLI signaling and stemness, we quantified the ability of dissociated, singlegliomasphere cells to generate secondary spheres as a measure of self-renewal ( Figures 4B and 4E) . Treatment of dissociated gliomasphere cells with cyclopamine for 7 days, prior to renewed dissociation and cloning without the drug, resulted in a reduction of w50%-65% in clones as compared to tomatidine treatment ( Figure 4C ). Because 7 days allows for approximately five cell divisions (calculated from BrdU incorporation data), giving rise to a 32-cell gliomasphere derived from a single cell (assuming constant division rates), and the cloning rate was at 6%-7%, there are on average two clonogenic stem cells per 32-cell sphere. Given that cyclopamine treatment for 7 days also decreased sphere volume-but not cell size-by w50% ( Figure 4B ), as it also affected growth, we deduced that cyclopamine treatment reduced the number of cancer stem cells to 0.3-0.5 per sphere on average, thus rendering them nonviable, consistent with the lack of recovery after long-term cyclopamine treatment ( Figure S6E ). Transient inhibition of SMOH (with DOX) for 7 days prior to not shown for histograms denoting ratios, but significance is provided by asterisks (p < 0.05). PC denotes pineocytoma, and NC denotes neurocytoma. (E and F) Rescue of the effects of cyclopamine by siRNA GLI3. The incompleteness of the effect is likely due to partial siRNA lipofection compared with the ubiquitous effects of the drug. GLI1 or GLI2 siRNAs did not rescue the effects of cyclopamine (not shown). Asterisks denote significative (p < 0.05) changes.
cloning mimicked the results obtained with cyclopamine ( Figure 4D ). Similar treatment with recombinant SHH, in contrast, increased the number of clones by w145%-240% ( Figure S9A ). Because SHH treatment increased sphere volume w3-4-fold on average ( Figure 4B ), it induced an increase in the number of glioma stem cells to w10-20 per sphere. Similar experiments with TMZ showed that it does not significantly affect cancer stem cell self-renewal (p = 0.3, 50 mM TMZ versus treatment with dimethyl sulfoxide [DMSO] carrier alone).
We used CD133 expression to purify glioma-initiating cancer stem cells by fluorescence-and magnetic-activated cell sorting (FACS, MACS) [5, 6] (Figure 4E ). The percentage of secondary clones from CD133 + MACSsorted GBM-8 cells was 40-fold higher as compared with CD133
2 cells. The percentage of secondary spheres from four gliomasphere cultures was on average 2.3-fold lower than the percentage of FACS-sorted CD133 + cells (Figure S10B ), raising the possibility that not all CD133 + cells are cancer stem cells as determined by clonogenic behavior, consistent with the variability of CD133 expression ( Figures 1A and 4A ). Analysis of a subset of genes in CD133 + versus CD133 2 cells showed that SHH was enriched in all samples, whereas NOTCH1 was enriched in all efficient cultures (Figures S10A and S10B). There was also a correlation between efficiency of sphere formation (quality) and stemnessmarker expression ( Figure S10 ).
Cyclopamine treatment of CD133 + cells for 7 days prior to cloning without the drug (see Figure 4E ) reduced the number of clones by w20%-45% ( Figure 4F ). This result was observed in sphere cultures after several passages as well as in CD133 + cells freshly purified from a patient's GBM ( Figure 4F) . Conversely, SHH treatment increased secondary-sphere formation by 120%-140% ( Figure S9B ). The clonogenicity decrease resulting from inhibition of endogenous HH-GLI signaling was correlated with a coordinated decrease in GLI1, PTCH1, and SHH expression at the time of cloning, but also with the specific and coordinated downregulation of stemness-gene expression ( Figure 4G ). Treatment of freshly MACS-sorted CD133 + cells with cyclopamine for only 4 hr resulted in a decrease in GLI1, PTCH1, NANOG, SOX2, and OCT4 expression by 50%, 40%, 10%, 57%, and 20% for GBM-8 (and in GMB-6, not shown), respectively, as compared with cyclopaminetreated CD133
2 cells, strongly suggesting the direct inhibition of HH-GLI signaling by cyclopamine and the regulation of stemness genes by this pathway.
Here, we demonstrate that human gliomas and their cancer stem cells require HH-GLI pathway activity for proliferation, survival, self-renewal, and tumorigenicity. The widespread expression of GLI1 in gliomas is consistent with its isolation from a glioma cell line [13] and its expression in brain tumors in situ [7] . The discrepancy with previous work, suggesting that GLI1 was not overexpressed in gliomas [14] , can be partly explained by the fact that the cerebellum, which we now know expresses GLI1 at the highest levels [15] , was used as the baseline. We have also uncovered a stemness signature that we interpret to denote the abundance of cancer stem cells in grade III gliomas. Cancer stem cells in GBMs may become diluted by the increased number of more differentiated tumor-derived cells, which gives them their multiforme character, and by the enhanced participation of nontumor cells in GBMs, for instance through increased angiogenesis. Interestingly, angiogenesis in gliomas could not only provide required nutrients to the tumor but also enhance its growth and cancer stem cell self-renewal in cases when new vessels express SHH. Whereas glioma cancer stem cells express markers of endogenous stem cells [4, 16, 17] , the origin of the former is unclear. They could arise through a dedifferentiation process or derive from precursors or endogenous brain stem cells [16, [18] [19] [20] . Paralleling the derivation of medulloblastomas from SHH-dependent GLI1 + cortical cerebellar cells [7, 15, 21] , glioma and other cancer stem cells could derive from endogenous GLI1 + cells, including those found in stem cell niches [7, 15, [22] [23] [24] [25] .
Our results argue for the development of antagonists of GLI1,2 and agonists of GLI3R as anticancer agents. Given that cyclopamine induces both of these changes simultaneously and shows additive and synergistic effects with TMZ, a combinatorial approach with these agents may be advantageous to the treatment of the tumor bulk and its cancer stem cells. The findings that HH-GLI signaling is involved in regulating the proliferation of both endogenous brain stem cells [22] [23] [24] [25] and glioma cancer stem cells (this work), and the lack of obvious secondary effects in cyclopamine-treated adult mice ( [23, 26] , this work), allow us to suggest that such treatments may spare normal quiescent stem cells in their niches, likely allowing regeneration of any damage to normal adult tissues after cessation of treatment.
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